|
|
| A Full-Service Outsourcing Partner with 97% Customer Retention | inSeption Group offers a full-service solution designed to disrupt the current outsourcing paradigm, resurrecting a common-sense approach to rebuild business trust and confidence in a client’s selected vendor. Primarily focused on oncology, hematology, neurodegenerative disorders, and rare/orphan disease indications, with a specialization in cell and gene therapy, inSeption has been a solution for its’ clients who have experienced the progressive degradation of today’s outsourcing options. Contact them. |
|
|
|
|
By Antony Hitchcock, principal and owner, AGH Bioconsulting | FDA's draft guidance on platforms is mostly for established, well-characterized modalities, but it also has implications for the emerging area of personalized medicine. |
|
|
|
| Level Up Your Supply Chain Initiatives | Article | IQVIA Technologies | Shipping and storing advanced therapeutics are complex processes, but advancements in accountability, wearables, and technology capture real-time factors critical to safety and protocol. |
|
|
|
| Overcoming Cell Therapy Supply Chain Challenges | Article | By Bill Shingleton, Cytiva | For the industry to realize the potential of cell and gene therapies (CGTs), we must develop improved solutions that reliably support the control and transport of critical CGT raw materials and products. |
|
|
|
|
|
.png){kind=logo}
